Phase I/II study of sunitinib malate in combination with gefitinib in patients (pts) with metastatic renal cell carcinoma (mRCC)

被引：0
|
作者：
Patel, P. H.
Kondagunta, G. V.
Redman, B. G.
Hudes, G. R.
Kim, S. T.
Chen, I.
Motzer, R. J.
机构：
[1] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
[2] Univ Michigan, Ann Arbor, MI 48109 USA
[3] Fox Chase Canc Ctr, Philadelphia, PA 19111 USA
[4] Pfizer Inc, San Diego, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2007年 / 25卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5097
引用
下载
收藏
页数：1
相关论文
共 50 条
  • [31] Phase I Trial of Sunitinib Malate plus Interferon-α for Patients with Metastatic Renal Cell Carcinoma
    Motzer, Robert J.
    Hudes, Gary
    Wilding, George
    Schwartz, Lawrence H.
    Hariharan, Subramanian
    Kempin, Susan
    Fayyad, Rana
    Figlin, Robert A.
    CLINICAL GENITOURINARY CANCER, 2009, 7 (01) : 28 - 33
  • [32] Outcomes of sunitinib therapy in patients (pts) with metastatic renal cell carcinoma (mRCC) with poor risk features
    Barroso-Sousa, Romualdo
    Munhoz, Rodrigo Ramella
    Fonseca, Leonardo Gomes
    de Sousa Fede, Angelo Bezerra
    Marques Linck, Rudinei Diogo
    Venchiarutti Moniz, Camila Motta
    Mak, Milena Perez
    Souza, Ciro Eduardo
    Hoff, Paulo M.
    Dzik, Carlos
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (06)
  • [33] Are there geographic differences in the outcome of patients (pts) with metastatic renal cell carcinoma (mRCC) treated with sunitinib (su)?
    Keizman, Daniel
    Ish-Shalom, Maya
    Maimon, Natalie
    Gottfried, Maya
    Pili, Roberto
    Hammers, Hans J.
    Eisenberger, Mario A.
    Sinibaldi, Victoria J.
    Boursi, Ben
    Weitzen, Rony
    Hayat, Henry
    Peer, Avivit
    Neumann, Avivit
    Kovel, Svetlana
    Sella, Avishay
    Mermershtain, Wilmosh
    Rouvinov, Keren
    Berger, Raanan
    Carducci, Michael Anthony
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [34] A pooled analysis of the efficacy and safety of sunitinib in elderly patients (pts) with metastatic renal cell carcinoma (mRCC).
    Hutson, T. E.
    Bukowski, R. M.
    Rini, B. I.
    Gore, M. E.
    Larkin, J. M. G.
    Figlin, R. A.
    Barrios, C. H.
    Escudier, B.
    Lin, X.
    Fly, K. D.
    Martell, B.
    Matczak, E.
    Motzer, R. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [35] Hypertension and myelosuppression as biomarkers of sunitinib efficacy in Chinese patients (pts) with metastatic renal cell carcinoma (mRCC)
    Qin, Shukui
    Jin, Jie
    Guo, Jun
    Wang, Jin-Wan
    Zhou, Fang-Jian
    Huang, Yi-Ran
    Ren, Xiu-Bao
    Ye, Ding-Wei
    Pan, Sharon
    Sajben, Peter
    Wang, Qiao
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (06)
  • [36] Are there geographic differences in the outcome of patients (pts) with metastatic renal cell carcinoma (mRCC) treated with sunitinib (su)?
    Keizman, Daniel
    Ish-Shalom, Maya
    Maimon, Natalie
    Gottfried, Maya
    Pili, Roberto
    Hammers, Hans J.
    Eisenberger, Mario A.
    Sinibaldi, Victoria J.
    Boursi, Ben
    Weitzen, Rony
    Hayat, Henry
    Peer, Avivit
    Neumann, Avivit
    Kovel, Svetlana
    Sella, Avishay
    Mermershtain, Wilmosh
    Roubinov, Keren
    Berger, Raanan
    Carducci, Michael Anthony
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (06)
  • [37] Safety and efficacy of AMG 386 in combination with sunitinib in patients with metastatic renal cell carcinoma (mRCC) in an open-label multicenter phase II study
    Atkins, Michael B.
    Ravaud, Alain
    Gravis, Gwenaelle
    Drosik, Kazimierz
    Demkow, Tomasz
    Tomczak, Piotr
    Kracht, Karolyn
    Puhlmann, Markus
    Weinreich, David Michael
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [38] SUNITINIB IN PATIENTS (PTS) WITH OR WITHOUT PRIOR NEPHRECTOMY IN AN EXPANDED-ACCESS STUDY OF METASTATIC RENAL CELL CARCINOMA (MRCC)
    Szczylik, C.
    Porta, C.
    Bracarda, S.
    Hawkins, R.
    Bjarnason, G. A.
    Oudard, S.
    Kee, S. H.
    Carteni, G.
    Hariharan, S.
    Gore, M.
    EUROPEAN UROLOGY SUPPLEMENTS, 2009, 8 (04) : 182 - 182
  • [39] Phase I study of nivolumab in combination with ipilimumab (IPI) in metastatic renal cell carcinoma (mRCC)
    Hammers, H.
    Plimack, E. R.
    Infante, J. R.
    Ernstoff, M. S.
    Rini, B.
    Mcdermott, D. F.
    Razak, A.
    Pal, S. K.
    Voss, M. H.
    Sharma, P.
    Kollmannsberger, C.
    Heng, D. Y. C.
    Spratlin, J.
    Shen, Y.
    Kurland, J. F.
    Gagnier, P.
    Amin, A.
    BJU INTERNATIONAL, 2014, 114 : 8 - 8
  • [40] Phase I trial of sunitinib (S) and temsirolimus (T) in metastatic renal cell carcinoma (mRCC)
    Campbell, Matthew T.
    Millikan, Randall E.
    Altinmakas, Emre
    Xiao, Lianchun
    Tannir, Nizar M.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (04)
12345